Review article · 2017
Conference abstractPublished 31 Mar 2016
Nephroprotection by hypoglycemic agents: Do we have supporting data?
Universidad de Valencia, Spain Hospital General Universitario de Ciudad Real, Spain Hospital Universitario N S Candelaria, Spain Hospital Universitario Bellvitge, Spain Spanish Society of Nephrology, Spain Carlos III Researc
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Current therapy directed at delaying the progression of diabetic nephropathy includes intensive glycemic and optimal blood pressure control, renin angiotensin-aldosterone system blockade and multifactorial intervention. However, the renal protection provided by these therapeutic modalities is incomplete. There is a scarcity of studies analyzing the nephroprotective effect of antihyperglycemic drugs beyond their glucose lowering effect and improved glycemic control on the prevention and progression of diabetic nephropathy. This article analyzes the existing data about older and newer drugs as well as the mechanisms associated with hypoglycemic drugs apart from their well-known blood glucose lowering effect in the prevention and progression of diabetic nephropathy. Most of them have been tested in humans but with varying degrees of success. Although experimental data about most of antihyperglycemic drugs has shown a beneficial effect in kidney parameters, there is a lack of clinical trials that clearly prove these beneficial effects. The key question, however, is whether antihyperglycemic drugs are able to improve renal end-points beyond their antihyperglycemic effect. Existing experimental data are post hoc studies from clinical trials and supportive of the potential renal-protective role of some of them, especially in the cases of dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors. Dedicated and adequately powered renal trials with renal outcomes are necessary to assess the nephrotection of antihyperglycemic drugs beyond the control of hyperglycemia.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 2014
A Comparison of Data Driven-based Measures of Adherence to Oral Hypoglycemic Agents in Medicaid Patients
Conference abstract · 2018
Optimizing clinical trials as part of the totality of data to support the marketing approval of biosimilars
Article · 28 Feb 2025
A Study on In-Silico Supported Nephroprotective Action of Coccinia Species
Commentary · 2014
Phosphodiesterase-5 Inhibitors: Potential Nephroprotective Agents
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Research article · 15 Apr 2026
Anemia Management in Hemodialysis Patients in a Low-resource Setting: Blood Transfusion and Unmet Blood Needs in Burkina Faso
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Jose Luis Gorriz”
- BylineArticles whose byline prints “Javier Nieto”
- BylineArticles whose byline prints “Juan F Navarro-Gonzalez”
- BylineArticles whose byline prints “Pablo Molina”
- BylineArticles whose byline prints “Alberto Martinez-Castelao”
- BylineArticles whose byline prints “Luis M Pallardo”

